Drugs designed to improve endothelial function: Effects on erectile dysfunction

Alan W Shindel, S. Kishore, T. F. Lue

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Endothelial dysfunction (EtD) has emerged as a critical master pathway in the pathogenesis of both vascular disease and erectile dysfunction (ED). Drugs that have been developed for vascular diseases and/or found to have beneficial endothelial effects may be helpful in the management of ED. In this manuscript we summarize the current state of the art with respect to endothelial active drugs and discuss the evidence supporting their use in the management of ED. Pubmed query for the terms Endothelial dysfunction, erectile dysfunction, pharmaceuticals, "endothelium", "function", "pharmaceutical", "eNOS", "erectile dysfunction" and "erectile function" was conducted. Relevant articles were reviewed and summarized. A variety of cardiovascular medications have mechanisms of action that involve the endothelium. Examples include HMG-CoA Reductase inhibitors ("statins"), Angiotensin Converting Enzyme Inhibitors (ACEI), Angiotensin Receptor blockers (ARB), Endothelin Receptor Antagonists (ERA), certain beta blockers, and some oral hypoglycemics. Some of these drugs have been found to improve penile erection, although an endothelium dependent mechanism has not been conclusively demonstrated in all studies. Drugs that improve endothelial function in the cavernous arteries and the erectile tissues of the corpora cavernosa hold great promise in treating or at least minimizing the vascular damage that contributes to ED. ACEI and ARB appear to hold great promise in this regard, while statins and oral hypoglycemics may play a potentially useful role as adjunctive therapy for ED. Improvements in endothelial function may help reverse ED in some cases, which would be a marked improvement over management with currently available "on demand" ED therapies.

Original languageEnglish (US)
Pages (from-to)3758-3767
Number of pages10
JournalCurrent Pharmaceutical Design
Volume14
Issue number35
DOIs
StatePublished - 2008

Fingerprint

Erectile Dysfunction
Pharmaceutical Preparations
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Endothelium
Angiotensin Receptor Antagonists
Vascular Diseases
Angiotensin-Converting Enzyme Inhibitors
Hypoglycemic Agents
Penile Erection
Critical Pathways
PubMed
Blood Vessels
Arteries
Therapeutics

Keywords

  • Drugs
  • Endothelium
  • eNOS
  • Erectile dysfunction
  • Nitric oxide
  • Vascular disease

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Cite this

Drugs designed to improve endothelial function : Effects on erectile dysfunction. / Shindel, Alan W; Kishore, S.; Lue, T. F.

In: Current Pharmaceutical Design, Vol. 14, No. 35, 2008, p. 3758-3767.

Research output: Contribution to journalArticle

@article{5b80691a86be4c4cbf9d670fd28ba4ee,
title = "Drugs designed to improve endothelial function: Effects on erectile dysfunction",
abstract = "Endothelial dysfunction (EtD) has emerged as a critical master pathway in the pathogenesis of both vascular disease and erectile dysfunction (ED). Drugs that have been developed for vascular diseases and/or found to have beneficial endothelial effects may be helpful in the management of ED. In this manuscript we summarize the current state of the art with respect to endothelial active drugs and discuss the evidence supporting their use in the management of ED. Pubmed query for the terms Endothelial dysfunction, erectile dysfunction, pharmaceuticals, {"}endothelium{"}, {"}function{"}, {"}pharmaceutical{"}, {"}eNOS{"}, {"}erectile dysfunction{"} and {"}erectile function{"} was conducted. Relevant articles were reviewed and summarized. A variety of cardiovascular medications have mechanisms of action that involve the endothelium. Examples include HMG-CoA Reductase inhibitors ({"}statins{"}), Angiotensin Converting Enzyme Inhibitors (ACEI), Angiotensin Receptor blockers (ARB), Endothelin Receptor Antagonists (ERA), certain beta blockers, and some oral hypoglycemics. Some of these drugs have been found to improve penile erection, although an endothelium dependent mechanism has not been conclusively demonstrated in all studies. Drugs that improve endothelial function in the cavernous arteries and the erectile tissues of the corpora cavernosa hold great promise in treating or at least minimizing the vascular damage that contributes to ED. ACEI and ARB appear to hold great promise in this regard, while statins and oral hypoglycemics may play a potentially useful role as adjunctive therapy for ED. Improvements in endothelial function may help reverse ED in some cases, which would be a marked improvement over management with currently available {"}on demand{"} ED therapies.",
keywords = "Drugs, Endothelium, eNOS, Erectile dysfunction, Nitric oxide, Vascular disease",
author = "Shindel, {Alan W} and S. Kishore and Lue, {T. F.}",
year = "2008",
doi = "10.2174/138161208786898752",
language = "English (US)",
volume = "14",
pages = "3758--3767",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "35",

}

TY - JOUR

T1 - Drugs designed to improve endothelial function

T2 - Effects on erectile dysfunction

AU - Shindel, Alan W

AU - Kishore, S.

AU - Lue, T. F.

PY - 2008

Y1 - 2008

N2 - Endothelial dysfunction (EtD) has emerged as a critical master pathway in the pathogenesis of both vascular disease and erectile dysfunction (ED). Drugs that have been developed for vascular diseases and/or found to have beneficial endothelial effects may be helpful in the management of ED. In this manuscript we summarize the current state of the art with respect to endothelial active drugs and discuss the evidence supporting their use in the management of ED. Pubmed query for the terms Endothelial dysfunction, erectile dysfunction, pharmaceuticals, "endothelium", "function", "pharmaceutical", "eNOS", "erectile dysfunction" and "erectile function" was conducted. Relevant articles were reviewed and summarized. A variety of cardiovascular medications have mechanisms of action that involve the endothelium. Examples include HMG-CoA Reductase inhibitors ("statins"), Angiotensin Converting Enzyme Inhibitors (ACEI), Angiotensin Receptor blockers (ARB), Endothelin Receptor Antagonists (ERA), certain beta blockers, and some oral hypoglycemics. Some of these drugs have been found to improve penile erection, although an endothelium dependent mechanism has not been conclusively demonstrated in all studies. Drugs that improve endothelial function in the cavernous arteries and the erectile tissues of the corpora cavernosa hold great promise in treating or at least minimizing the vascular damage that contributes to ED. ACEI and ARB appear to hold great promise in this regard, while statins and oral hypoglycemics may play a potentially useful role as adjunctive therapy for ED. Improvements in endothelial function may help reverse ED in some cases, which would be a marked improvement over management with currently available "on demand" ED therapies.

AB - Endothelial dysfunction (EtD) has emerged as a critical master pathway in the pathogenesis of both vascular disease and erectile dysfunction (ED). Drugs that have been developed for vascular diseases and/or found to have beneficial endothelial effects may be helpful in the management of ED. In this manuscript we summarize the current state of the art with respect to endothelial active drugs and discuss the evidence supporting their use in the management of ED. Pubmed query for the terms Endothelial dysfunction, erectile dysfunction, pharmaceuticals, "endothelium", "function", "pharmaceutical", "eNOS", "erectile dysfunction" and "erectile function" was conducted. Relevant articles were reviewed and summarized. A variety of cardiovascular medications have mechanisms of action that involve the endothelium. Examples include HMG-CoA Reductase inhibitors ("statins"), Angiotensin Converting Enzyme Inhibitors (ACEI), Angiotensin Receptor blockers (ARB), Endothelin Receptor Antagonists (ERA), certain beta blockers, and some oral hypoglycemics. Some of these drugs have been found to improve penile erection, although an endothelium dependent mechanism has not been conclusively demonstrated in all studies. Drugs that improve endothelial function in the cavernous arteries and the erectile tissues of the corpora cavernosa hold great promise in treating or at least minimizing the vascular damage that contributes to ED. ACEI and ARB appear to hold great promise in this regard, while statins and oral hypoglycemics may play a potentially useful role as adjunctive therapy for ED. Improvements in endothelial function may help reverse ED in some cases, which would be a marked improvement over management with currently available "on demand" ED therapies.

KW - Drugs

KW - Endothelium

KW - eNOS

KW - Erectile dysfunction

KW - Nitric oxide

KW - Vascular disease

UR - http://www.scopus.com/inward/record.url?scp=61449238410&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61449238410&partnerID=8YFLogxK

U2 - 10.2174/138161208786898752

DO - 10.2174/138161208786898752

M3 - Article

C2 - 19128228

AN - SCOPUS:61449238410

VL - 14

SP - 3758

EP - 3767

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 35

ER -